RAPT Therapeutics (NASDAQ:RAPT) Stock Rating Reaffirmed by HC Wainwright

HC Wainwright restated their neutral rating on shares of RAPT Therapeutics (NASDAQ:RAPT) in a research note published on Tuesday, Benzinga reports. HC Wainwright also issued estimates for RAPT Therapeutics’ Q3 2024 earnings at ($0.63) EPS, Q4 2024 earnings at ($0.57) EPS, Q1 2025 earnings at ($0.63) EPS, Q2 2025 earnings at ($0.65) EPS, Q3 2025 earnings at ($0.68) EPS, Q4 2025 earnings at ($0.62) EPS and FY2025 earnings at ($2.58) EPS.

Other research analysts have also recently issued reports about the stock. Barclays cut shares of RAPT Therapeutics from an overweight rating to an equal weight rating and decreased their target price for the stock from $13.00 to $4.00 in a report on Friday, May 10th. Guggenheim cut shares of RAPT Therapeutics from a buy rating to a neutral rating in a report on Friday, May 10th. Finally, Wolfe Research reissued a peer perform rating on shares of RAPT Therapeutics in a report on Tuesday, May 14th. Nine analysts have rated the stock with a hold rating and two have issued a buy rating to the stock. According to data from MarketBeat, the company has an average rating of Hold and a consensus target price of $21.57.

RAPT Therapeutics Price Performance

NASDAQ:RAPT opened at $2.33 on Tuesday. RAPT Therapeutics has a one year low of $2.12 and a one year high of $27.35. The company’s 50-day simple moving average is $2.93 and its 200 day simple moving average is $6.92. The firm has a market capitalization of $81.32 million, a P/E ratio of -0.76 and a beta of 0.36.

RAPT Therapeutics (NASDAQ:RAPT) last posted its quarterly earnings data on Thursday, August 8th. The company reported ($0.71) EPS for the quarter, topping the consensus estimate of ($0.74) by $0.03. On average, equities research analysts expect that RAPT Therapeutics will post -2.75 earnings per share for the current fiscal year.

Institutional Trading of RAPT Therapeutics

Hedge funds and other institutional investors have recently added to or reduced their stakes in the business. China Universal Asset Management Co. Ltd. increased its holdings in RAPT Therapeutics by 65.8% during the first quarter. China Universal Asset Management Co. Ltd. now owns 6,602 shares of the company’s stock valued at $59,000 after buying an additional 2,621 shares during the last quarter. Acadian Asset Management LLC purchased a new stake in RAPT Therapeutics during the first quarter valued at approximately $97,000. XTX Topco Ltd purchased a new stake in RAPT Therapeutics during the second quarter valued at approximately $108,000. Hennion & Walsh Asset Management Inc. increased its holdings in RAPT Therapeutics by 8.6% during the second quarter. Hennion & Walsh Asset Management Inc. now owns 48,525 shares of the company’s stock valued at $148,000 after buying an additional 3,824 shares during the last quarter. Finally, EntryPoint Capital LLC purchased a new stake in RAPT Therapeutics during the first quarter valued at approximately $161,000. 99.09% of the stock is owned by hedge funds and other institutional investors.

RAPT Therapeutics Company Profile

RAPT Therapeutics, Inc, a clinical-stage immunology-based biopharmaceutical company, focuses on discovery, development, and commercialization of oral small molecule therapies for patients with unmet needs in oncology and inflammatory diseases in the United States. The company's lead inflammation drug candidate is zelnecirnon (RPT193), a C-C motif chemokine receptor 4 (CCR4) antagonist that selectively inhibit the migration of type 2 T helper cells into inflamed tissues.